MYERS: A good mayor takes a cause too far
I like Michael Bloomberg, the mayor of New York City. He says what he thinks and thinks about what he says.
Home » Search
Search Results
4,596 results for 'mental health'
- Sort By
-
Date
- Any Time
- Past Day
- Past Week
- Past Month
- Past Year
-
Custom Date Range
Articles
Slingshot SEO branches out after Google throws it for a loop
Search-engine optimization remains part of Slingshot SEO’s name. But one of the region’s fastest-growing tech companies is abruptly shifting strategy—in part because changes by Google have undercut its core business.
Alzheimer’s quest puts Lilly to test
Odds are long that Eli Lilly and Co.’s leading Alzheimer’s drug will show positive results when its Phase 3 trial results are released within a few weeks, but even the smallest improvement in the cognitive impairment of test patients would be a home run for Lilly.
Company news
Kansas-based Mediware Information Systems Inc. announced plans Monday to acquire the assets of Indianapolis-based Strategic Healthcare Group LLC, which provides blood management consulting and IT programs to blood centers and hospital systems. Financial terms of the deal were not disclosed. Strategic Healthcare was founded in 2006 by Dr. Timothy Hannon, offering to find cost savings for its customers and to improve safety for patients. Of particular interest to Mediware is Strategic Healthcare’s analytics technology called BloodStat, which has amassed the hospital industry’s largest database of clinical and financial information about blood use, which can serve as a benchmark for health care providers trying to improve their own use of blood. “We believe the combination of SHG’s products and expertise, with our software and large base of prestigious hospital customers, will provide additional growth opportunities and enhance our overall market position,” said Mediware CEO Thomas Mann in a prepared statement.
West Lafayette-based Endocyte Inc. thinks it can use the same technology that lies behind its experimental cancer treatments to treat polcystic kidney disease, too. The drug company announced Friday that tests of an experimental drug in mice slowed the development of cysts and preserved the function of the mice’s kidneys. Endocyte’s drug for kidney disease, EC0371, is a combination of folic acid and the drug rapamycin, an immunosuppressant often used during kidney transplants. Folic acid binds more readily with some diseased cells, which allows Endocyte’s drug combo to deliver a higher dose of a medicine without increasing side effects. That combination has appeared to prove more effective for treating some kinds of ovarian cancer, and Endocyte is moving to win approval for an ovarian cancer drug, known as EC145, in Europe.
The Indiana Health Information Exchange, based in Indianapolis, has added Greene County General Hospital in Linton to its medical-record-swapping network. That network, called the Indiana Network for Patient Care, now includes 90 hospitals and more than 20,000 physicians around the state. It processes more than 3 million exchanges of medical data every day, including laboratory results and medication histories. Swapping medical records is designed to reduce repeat procedures and cut down on medical errors, such as prescribing drugs that interact with one another.
Despite funding dip, IU bets on brains
The city that brought the world Prozac and other neuroscience drugs is doubling down on brain research with a new $52 million research center near Methodist Hospital.
KANE: Racist thoughts still tinge Black Expo
It has been unfortunate to hear the criticisms and judgmental rumblings regarding the decorum of expo visitors and tourists over the past few years.
Rising use of part-time faculty sparks worries
Some advocacy groups argue that an overreliance on part-time faculty can weaken the academic experience for students on campus.
Public safety due for budget cuts, mayor says
Public safety and criminal justice are the only places left in the city-county budgets to look for ways to close a $27 million spending gap for 2013. Sheriff, police, fire and court budgets account for 85 percent of the $569 million general fund.
Life Sciences Power Breakfast – transcript
Life sciences leaders discuss topics ranging from accomplishments to initial public offerings and the nature of innovation at the July 25 event.
Indiana life sciences companies rethink innovation
Research and development comes under pressure in an age of austerity.
Lilly’s quarterly profit falls, but tops analyst expectations
Eli Lilly and Co. reported second-quarter profit that fell less than analysts had expected. The company raised its outlook for the rest of the year.
Company news
Indiana University has received the go-ahead to begin the accreditation process for new schools of public health proposed for its Bloomington and Indianapolis campuses, according to the Associated Press. University officials said the step by the independent Council on Education for Public Health kicks off an expected two-year process to create schools of public health on IU's two largest campuses. The school on the Bloomington campus will focus on rural communities. The Indianapolis school will focus on urban health and health policy, as well as on collaborative work with the IU School of Medicine.
An antipsychotic drug that Eli Lilly and Co. hoped would be an improved replacement for Zyprexa failed in a late-stage study that compared patients taking the drug to those taking a placebo. The drug, known as pomaglumetad methionil, or mGlu 2/3, showed no difference versus a placebo. A control group of patients taking another drug, risperidone, which goes by the brand name Risperdal, did show a difference. Despite the failure, Lilly said it would continue to conduct two other clinical trials of the drug. Lilly is studying pomaglumetad methionil to see whether it can work as an antipsychotic without side effects like weight gain that come with current treatments. Zyprexa, which reached peak annual sales of $5 billion, lost its U.S. and European patent protection last fall.
A chain of dental offices that abruptly closed multiple Indiana locations in December 2010 left patients without care, refunds or records, according to a complaint filed by the Office of the Indiana Attorney General. Attorney General Greg Zoeller has filed a complaint against Allcare Dental & Dentures, which closed offices in Anderson, Avon, Evansville, Fort Wayne, Indianapolis, Mishawaka and Muncie. The complaint alleges multiple licensing violations against company President Robert Bates. The complaint says Allcare failed to reimburse patients who paid upfront for services that weren’t completed; failed to complete dental procedures in progress; didn’t provide dentures that were fabricated; and locked dentists out of their offices, rendering them unable to notify patients or transfer patient records as the law requires. Massachusetts, New Hampshire, North Dakota, Ohio and West Virginia also have taken actions against Bates’ dental licenses for similar violations. Bates has settled or been party to consent agreements with licensing boards of each of those states, according to the AG’s complaint. The Indiana State Board of Dentistry is scheduled to conduct a hearing on the complaint Oct. 5.
After six months of denying coverage for a $350 genetic test for each of three Indiana children, Indianapolis-based WellPoint Inc. reversed itself and will now pay for the tests, according to Bloomberg News. The father of the three children, Matthew Christman, has an inherited heart disease that often strikes without warning. Since December, WellPoint’s Anthem Blue Cross and Blue Shield unit had denied paying for the test, saying it was “experimental” and “not medically necessary,” according to Bloomberg. The test is made by New Jersey-based Bio-Reference Labs Inc.
Lilly gets boost in Alzheimer’s race
Eli Lilly and Co. got a boost of confidence last week that its project to launch the first effective Alzheimer’s treatment is on the right track—though it still faces hugely long odds.
WellPoint agrees to pay for 3 children to get gene test
WellPoint Inc. said it will pay for DNA testing for three children to see if they have an inherited heart disease their father suffers from that often strikes without warning, reversing an earlier decision to deny coverage.
Competing Alzheimer’s treatments facing long odds
Johnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms. Analysts say the potential drugs are long shots.
TAFT: Institutions must invest in neighborhoods
Local government should encourage such partnerships.
SWAYZE: Voters ready to retrieve turf from the left
Most in the political industry are continuing old-school tactics.